← Leaderboards
Hyam Isaac Levitsky
Johns Hopkins University
$7,128,026
Attributed
$7,128,026
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–16$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$7,128,026 · 12
By mechanism
P01$2,829,159 · 2
R01$2,265,215 · 3
U54$970,794 · 1
R21$603,316 · 1
P30$442,051 · 1
M01$17,491 · 3
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Drew M. Pardoll$27,059,898
- Lei Zheng$11,028,048
- Katherine B Chiappinelli$3,587,162
- Elizabeth Marion Jaffee$29,780,612
- Richard J Jones$17,555,212
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseImmune ResponseVaccinesT-LymphocyteCellsMediatingImmuneClinical TrialsImmunityTumorAntigensResponseHematopoietic Stem CellsMouse ModelCancer CellProceduresMalignant NeoplasmsVaccinationVaccine AntigenCancer VaccinesTumor AntigensRelapseRelative (Related Person)Antigen-Presenting Cells
Grant awards (31)
Augmenting Antitumor Immunity$442,759
P01 · FY2016 · CA · contact PI
Augmenting Antitumor Immunity$442,759
P01 · FY2015 · CA · contact PI
Augmenting Antitumor Immunity$429,477
P01 · FY2014 · CA · contact PI
Non-Invasive Quantification of Vaccine-Mediated Antigen Delivery to$184,189
U54 · FY2014 · CA · contact PI
Augmenting Antitumor Immunity$416,194
P01 · FY2013 · CA · contact PI
Non-Invasive Quantification of Vaccine-Mediated Antigen Delivery to$290,635
U54 · FY2013 · CA · contact PI
Augmenting Antitumor Immunity$420,228
P01 · FY2012 · CA · contact PI
Non-Invasive Quantification of Vaccine-Mediated Antigen Delivery to$280,970
U54 · FY2012 · CA · contact PI
Regulatory T cells in B cell lymphoma$330,091
R01 · FY2011 · CA · contact PI
Immunologic targets in Myeloid Leukemia$330,091
R01 · FY2011 · CA · contact PI
Immunologic targets in Myeloid Leukemia$340,300
R01 · FY2010 · CA · contact PI
Regulatory T cells in B cell lymphoma$340,300
R01 · FY2010 · CA · contact PI
Non-Invasive Quantification of Vaccine-Mediated Antigen Delivery to$215,000
U54 · FY2010 · CA · contact PI
HUMAN IMMUNOLOGY$113,952
P30 · FY2010 · CA · contact PI
Regulatory T cells in B cell lymphoma$340,300
R01 · FY2009 · CA · contact PI
HUMAN IMMUNOLOGY$115,518
P30 · FY2009 · CA · contact PI
HUMAN IMMUNOLOGY$45,544
P30 · FY2009 · CA · contact PI
Regulatory T cells in B cell lymphoma$340,300
R01 · FY2008 · CA · contact PI
HUMAN IMMUNOLOGY$55,679
P30 · FY2008 · CA · contact PI
HUMAN IMMUNOLOGY$55,679
P30 · FY2007 · CA · contact PI
VACCINATION IN COMBINATION WITH IMATINIB MESYLATE FOR CHRONIC MYELOID LEUKEMIA$225
M01 · FY2007 · RR · contact PI
HUMAN IMMUNOLOGY$55,679
P30 · FY2006 · CA · contact PI
K562/GM-CSF VACCINATION$9,042
M01 · FY2006 · RR · contact PI
Cancer Vaccines in the Treatment of CML$301,658
R21 · FY2005 · CA
K562/GM-CSF VACCINATION$8,224
M01 · FY2005 · RR
Cancer Vaccines in the Treatment of CML$301,658
R21 · FY2004 · CA
TUMOR VACCINES$225,914
P01 · FY2002 · CA
Immunotherapy for B cell lymphoma$0
P50 · FY2002 · CA
TUMOR VACCINES$225,914
P01 · FY2001 · CA
TUMOR INDUCED ANTIGEN SPECIFIC T CELL TOLERANCE$243,833
R01 · FY2000 · CA
TUMOR VACCINES$225,914
P01 · FY2000 · CA